Europe panel recommends HIV drug Atripla |
|
|
|
Published
:
Thu, 18 Oct 2007 20:18
|
NEW YORK (AP) - Gilead Sciences Inc., Bristol-Myers Squibb Co. and Merck & Co. Inc. said Thursday a European Union panel recommended its once-a-day HIV pill Atripla be approved for sale.The Committee for Medicinal Products for Human Use, part of the European Medicines Agency, or EMEA, said the drug should be approved for adults who have not been treated with other therapies. Atripla combines three drugs: efavirenz, emtricitabine and tenofovir.Bristol-Myers Squibb and Merck share marketing rights for efavirenz, while emtricitabine and tenofovir are Gilead drugs.The companies said they expect the full European Medicines Agency, or EMEA, to rule on Atripla by the end of 2007.The EMEA reviews products for use in the 27 countries of the European Union.Gilead shares rose $1.07, or 2.5 percent, to $43.74 in afternoon trading, and set an all-time high of $43.99.Merck shares gained 7 cents to $53.35.Bristol-Myers shares slipped 29 cents to $29.54.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
Print this Story
European CHMP Issues Positive Opinion for Atripla 